Elite Pharmaceuticals, Inc.
specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tablets, pellets, capsules, granules and powders.
The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.
The Rodman & Renshaw 16th Annual Global
Live presentation on September. 9, 2014
at 2:55 PM Eastern
replay available until December 18, 2014
Recent Press Releases:
||ELITE PHARMACEUTICALS RELEASES POSITIVE TOP LINE HUMAN ABUSE LIABILITY DATA FOR ELI-200, AN OPIOID ABUSE DETERRENT PRODUCT
HAL study compared subjective effects of drug liking, drug high and good drug effects between ELI-200 and the comparator formulation in non-dependent recreational drug users
||ELITE PHARMACEUTICALS TO PRESENT AT THE 16TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE IN NEW YORK CITY SEPTEMBER 8-10TH
||Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015
Revenues Increase by 61%, Product Development on Schedule
Conference Call Scheduled for Monday, August 18th at 11:00 AM EDT
||Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on August 18, 2014
….First Quarter Financials for Fiscal Year 2015 Are Scheduled To Be Filed on Thursday, August 14, 2014
||Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201